治疗红色肌痛疗法的比较有效性和耐受性:系统性审查
Abdullah S Algarni1, Reem M Alharthi2, Shaden O Alqurashi3
1Department of Medicine, College of Medicine, University of Jeddah, Jeddah 23218, Saudi Arabia.
Medicina (Kaunas, Lithuania)
|May 28, 2025
概括
本综述比较了红色红斑症 (EM) 的医疗治疗方法,发现有效性和耐受性各不相同. 个性化护理和进一步的研究对于管理这种使人衰弱的疾病至关重要.
科学领域:
- 医学研究 医学研究
- 临床药理学 临床药理学
- 系统性审查 系统性审查
背景情况:
- 红色肌痛 (Erythromelalgia,简称EM) 是一种罕见的,使人衰弱的疾病,会导致四肢发红,灼热,疼痛和温暖.
- 对EM的有效治疗选择有限,严重影响患者的生活质量.
研究的目的:
- 系统地审查和比较可用于治疗红色红斑症的医疗治疗的有效性和安全性.
- 评估EM患者症状管理的各种干预措施.
主要方法:
- 在PubMed,Medline和Web of Science数据库中进行了系统的文献搜索,遵循PRISMA指南.
- 关键词包括"红色素质"或"米切尔病"和"红色素质治疗"或"红色素质管理".
主要成果:
- 涉及120名患者的6项研究评估了诸如伊洛普罗斯特,米索普罗斯托尔,局部阿米西林-胺,利多卡因和化学腰部同情切除等干预措施.
- 在疼痛减轻,冷却得分和温度调节方面观察到显著的改善.
- 伊洛普罗斯特和米索普罗斯托在降温,交感功能障碍和EM严重性方面表现出好处;局部阿米二胺在75%的患者中减轻了疼痛.
结论:
- 对EM的医疗干预提供了临床益处,但具有不同的耐受性和潜在的不良事件,需要仔细监测.
- 个性化治疗方法,包括基因测试和多学科护理,是必不可少的,因为EM的表现和并发症的多样性.
- 进一步的研究对于了解EM病理生理学和提高患者护理策略至关重要.
相关概念视频
01:22Dose-Response Relationship: Potency and Efficacy
5.3K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
5.3K
01:21Rheumatic Heart Disease III: Medical Management
36
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
36
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
3.7K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
3.7K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
706
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
706
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
228
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
228
01:16Bioequivalence: Overview
1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K